Immunovant (IMVT) Interest & Investment Income (2019 - 2026)

Immunovant's (IMVT) quarterly Interest & Investment Income came in at $1.0 million in Q3 2019, up 200.01% on a QoQ basis from $341558.0 in Q2 2019.

Analysis

Immunovant (IMVT) Interest & Investment Income (2019 - 2026) Analysis & Trends

Immunovant (IMVT) has 1 years of Interest & Investment Income data on file, last reported at $1.0 million in Q3 2019.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Int & Inv Inc (Qtr)
1	Vertex Pharmaceuticals	139.31 Bn	131.46 Bn	2.84 Bn	120.60 Mn
2	Regeneron Pharmaceuticals	85.65 Bn	77.66 Bn	3.93 Bn	-48.00 Mn
3	Argenx Se	63.46 Bn	58.27 Bn	1.37 Bn	48.00 Mn
4	Moderna	57.94 Bn	52.80 Bn	52.00 Mn	67.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	35.58 Mn
6	BeOne Medicines	39.96 Bn	34.86 Bn	1.53 Bn	27.90 Mn
7	Alnylam Pharmaceuticals	35.16 Bn	31.85 Bn	992.69 Mn	28.14 Mn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	5.13 Mn
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	10.98 Mn
10	Immunovant	8.04 Bn	8.04 Bn	-	7.10 Mn

Historic Data

Download Data